Find research datasets worth reusing
Search datasets from major research repositories and use ShareScore to quickly assess how well each record supports discovery, access, and reuse.
12,683
datasets available to search
ShareScore release 0.9.0
Dataset results
12,683 results for “tolerability”
A Study to Evaluate Tolerability of Two Topical Drug Products in the Treatment of Facial Acne
ClinicalTrials.gov study NCT00964223. IPD Sharing: YES. Countries: 1. Publications: 1.
Efficacy, Safety, and Tolerability of Valbenazine for the Treatment of Chorea Associated With Huntington Disease
ClinicalTrials.gov study NCT04102579. IPD Sharing: NO. Countries: 2. Publications: 2.
Study of Efficacy, Safety and Tolerability of Levodopa-Carbidopa Intestinal Gel in Levodopa-Responsive Parkinson's Subjects
ClinicalTrials.gov study NCT00357994. IPD Sharing: Not stated. Countries: 2. Publications: 3.
Randomized Study to Evaluate the Effect of Obicetrapib on Top of Maximum Tolerated Lipid-Modifying Therapies
ClinicalTrials.gov study NCT05142722. IPD Sharing: NO. Countries: 8. Publications: 3.
A 6-Month Open-Label Extension Study to the B2061014 Study to Evaluate the Safety, Tolerability and Efficacy of DVS SR in the Treatment of Children and Adolescents With MDD
ClinicalTrials.gov study NCT01371721. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Efficacy and Safety of Alirocumab Versus Placebo on Top of Maximally Tolerated Lipid Lowering Therapy in Patients With Hypercholesterolemia Who Have Type 1 or Type 2 Diabetes and Are Treated With Insu
ClinicalTrials.gov study NCT02585778. IPD Sharing: Not stated. Countries: 10. Publications: 3.
Efficacy, Safety, and Tolerability Study of Sotagliflozin as Adjunct Therapy in Adult Patients With Type 1 Diabetes Mellitus Who Have Inadequate Glycemic Control With Insulin Therapy
ClinicalTrials.gov study NCT02421510. IPD Sharing: Not stated. Countries: 17. Publications: 5.
Treatment Seeking Participants With Opioid Use Disorders Assessing Tolerability of Depot Injections of Buprenorphine
ClinicalTrials.gov study NCT02357901. IPD Sharing: NO. Countries: 1. Publications: 7.
Efficacy, Safety, and Tolerability of Gebasaxturev (V937) Administered Intravenously or Intratumorally With Pembrolizumab (MK-3475) Versus Pembrolizumab Alone in Participants With Advanced/Metastatic
ClinicalTrials.gov study NCT04152863. IPD Sharing: YES. Countries: 11. Publications: 1.
Study to Assess Efficacy, Safety, Tolerability and Pharmacokinetics of Simeprevir, Daclatasvir and Sofosbuvir in Treatment-naive Participants With Chronic Hepatitis C Virus Genotype 1 Infection
ClinicalTrials.gov study NCT02349048. IPD Sharing: Not stated. Countries: 2. Publications: 1.
Safety and Tolerability of Fingolimod in Patients With Relapsing-remitting Multiple Sclerosis
ClinicalTrials.gov study NCT01497262. IPD Sharing: Not stated. Countries: 8. Publications: 1.
A Study to Evaluate the Effectiveness, Safety, and Tolerability of Canagliflozin in Combination With Metformin in the Treatment of Patients With Type 2 Diabetes Mellitus With Inadequate Glycemic Contr
ClinicalTrials.gov study NCT01809327. IPD Sharing: Not stated. Countries: 13. Publications: 1.
Belatacept Post Depletional Repopulation to Facilitate Tolerance
ClinicalTrials.gov study NCT00565773. IPD Sharing: Not stated. Countries: 1. Publications: 5.
An Open-Label Study to Evaluate the Long-Term Safety, Tolerability, and Efficacy of OV101 in Individuals With Angelman Syndrome
ClinicalTrials.gov study NCT03882918. IPD Sharing: NO. Countries: 2. Publications: 1.
Study of the Clinical Activity, Safety, and Tolerability of SRT2104 in Subjects With Moderate to Severe Plaque-Type Psoriasis
ClinicalTrials.gov study NCT01154101. IPD Sharing: YES. Countries: 1. Publications: 1.
Promoting Tolerance to Peanut in High-Risk Children
ClinicalTrials.gov study NCT00329784. IPD Sharing: YES. Countries: 1. Publications: 9.
A Study to Assess the Safety, Tolerability and Efficacy of OP0201 as an Adjunct Treatment for Acute Otitis Media in Infants and Children Aged 6 to 24 Months
ClinicalTrials.gov study NCT03818815. IPD Sharing: NO. Countries: 1. Publications: 1.
Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN)
ClinicalTrials.gov study NCT03945318. IPD Sharing: YES. Countries: 3. Publications: 1.
A Study to Evaluate the Efficacy, Safety, and Tolerability of Rozanolixizumab in Adult Study Participants With Persistent or Chronic Primary Immune Thrombocytopenia (ITP)
ClinicalTrials.gov study NCT04200456. IPD Sharing: YES. Countries: 16. Publications: 1.
An Extension Study to Further Evaluate the Safety, Tolerability of GBT440 in Patients With Sickle Cell Disease Who Participated in the Study GBT440-001
ClinicalTrials.gov study NCT03041909. IPD Sharing: YES. Countries: 1. Publications: 1.
ScienceDex guides
Understand access before you commit
These curated guides explain access requirements, typical timelines, costs, and reuse considerations for widely used research datasets.
Allen Brain Atlas
Allen Brain Atlas is an Allen Institute collection of brain map atlases, datasets, APIs, and analysis tools covering mouse, human, and non-human primate brain resources.
Annotated Behaviour and Observability Dataset (ABODe)
ABODe is a University of Edinburgh DataShare dataset for behavior classification in group-housed mice using home-cage video, identities, bounding boxes, ground-plate positions, and annotator labels.
DANDI Archive for NWB datasets
DANDI is a BRAIN Initiative archive for publishing and sharing neurophysiology data, including electrophysiology, optophysiology, and behavioral data packaged as NWB and related standards.
International Brain Laboratory public data
The International Brain Laboratory public data releases expose standardized mouse decision-making experiments, including Neuropixels recordings, widefield calcium imaging, behavior, and session metadata accessed through the ONE API.
OpenNeuro
OpenNeuro is a free, open platform for sharing neuroimaging datasets, with public search, dataset pages, and download paths for web, S3, DataLad, and the OpenNeuro CLI.